NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
May 17 2022 - 3:15PM
Business Wire
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the
‘‘Company’’), a late-clinical stage biotechnology company
pioneering physics-based approaches to expand treatment
possibilities for patients with cancer, today announced that
Laurent Levy, co-founder and chairman of the executive board, and
Bart Van Rhijn, chief financial officer, will participate in the
Jefferies Healthcare Conference in June 2022.
Event Details:
Jefferies Healthcare Conference
- Presentation Date: Wednesday, June 8th, 2022
- Time: 1:00 PM ET
A live webcast of the presentation will be available on the
events page of the Investors section of the Company’s website. A
replay will be available on the Nanobiotix website within 48 hours
of the event. The Company’s corporate presentation can be
downloaded here.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company
pioneering disruptive, physics-based therapeutic approaches to
revolutionize treatment outcomes for millions of patients;
supported by people committed to making a difference for humanity.
The company’s philosophy is rooted in the concept of pushing past
the boundaries of what is known to expand possibilities for human
life.
Incorporated in 2003, Nanobiotix is headquartered in Paris,
France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, and Germany.
Nanobiotix has been listed on the regulated market of Euronext in
Paris since 2012 and on the Nasdaq Global Select Market in New York
City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous system.
The company's resources are primarily devoted to the development of
its lead product candidate– NBTXR3 —which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
www.nanobiotix.com or follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220517006155/en/
Nanobiotix
Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Investor Relations Department Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com
Media Relations
FR – Ulysse Communication Pierre-Louis Germain + 33 (0) 6
64 79 97 51 plgermain@ulysse-communication.com
US – Porter Novelli Caitlin Hunt +1 (781) 985-5967
Caitlin.hunt@porternovelli.com
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Feb 2025 to Mar 2025
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Mar 2024 to Mar 2025
